Trials / Completed
CompletedNCT05109702
A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye
A Phase 3, Multicenter, Randomized, Double Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution 0.25% Compared to Placebo in Subjects With Dry Eye
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 260 (actual)
- Sponsor
- HanAll BioPharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study was to compare the safety and efficacy of tanfanercept ophthalmic solution 0.25% with placebo for the treatment of the signs and symptoms of dry eye.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 0.25% Tanfanercept Ophthalmic Solution | Tanfanercept ophthalmic solution. |
| DRUG | Placebo | Placebo vehicle solution. |
Timeline
- Start date
- 2021-11-18
- Primary completion
- 2022-05-06
- Completion
- 2022-05-06
- First posted
- 2021-11-05
- Last updated
- 2023-10-23
- Results posted
- 2023-10-23
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05109702. Inclusion in this directory is not an endorsement.